Diagnosis of severe heterogeneous pulmonary emphysema (at least 10% of total lung parenchyma or 25% of target lobe with density \< -950HU);
Heterogeneity\> 15pp (difference of at least 15 percentage points of lung parenchyma with density greater than -950HU between the treated lobe(s) and the remaining lung on the same side)
Estimates of low or non-existent collateral ventilation (fissure integrity\> 95% measured by VIDA Diagnostics or collateral ventilation measured by negative Chartis® System)
Total lung capacity\> 100% of predicted
Residual volume\> 175% of predicted
FEV1 \<50% of predicted post-bronchodilator
DLCO (diffusing capacity of the lungs for carbon monoxide) \<45% of predicted post-bronchodilator
Body Mass Index (BMI) Greater than 18Kg/m2 and less than 35Kg/m2.
Optimized clinical treatment
Daily physical activities limitation
Possibility of pulmonary rehabilitation
Preserved ventricular function (LVEF\> 40%)
Cessation of smoking ≥ 4 months
Dyspnea MMRC ≥ 2
You may not be if
Homogeneous emphysema
Estimated collateral ventilation observed on CT scanned by VIDA vision software (VIDA vision®, VIDA Diagnostics, Iowa-USA) - Fissure integrity on target lobe less than 75%.
Use of continuous systemic corticosteroid therapy\> 20mg QD (quaque die, once a day) of prednisone (or equivalent)
Active lung or extra pulmonary infection
Coronary heart disease and/or severe ventricular dysfunction
Significant renal or hepatic disease
Immunosuppressive disease
Rheumatologic or orthopedic disease limiting physical capacity;
Cognitive inability to understand study procedures;
Impression by clinical research investigators with a lifespan of less than a year1;
Active smoking
Malignant neoplasia with estimated prognosis of survival \<2 years
Psychosocial problems
Pregnancy
Clareo Health | Cell Therapy Associated With Endobronchial Valve
